TRIPS-Plus IP demands from EU could halt South American trade deal
This article was originally published in Scrip
Executive Summary
Free trade negotiations between the EU and the Latin American trade bloc Mercosur (Argentina, Brazil, Paraguay and Uruguay) are at a standstill, in part at least because of demands from the EU that Mercosur introduce tougher measures to protect intellectual property rights. At a time when Brazil is endeavouring to become more self-sufficient in pharmaceutical production and Argentina is imposing bans on drug importation (scripintelligence.com, 6 June 2011), it is unsurprising that Mercosur opposes EU proposals for 5-year patent extension for drugs and 10-year data exclusivity.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.